Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial
SAN DIEGO — Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms.
Article content
Through this collaboration, LabPMM (Invivoscribe's global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to support CERo's clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML.
Article content
AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis. 1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chimeric antigen receptor T-cells) and Chimeric Engulfment Receptor T-cells ('CER-T') therapies, which involve engineering a patient's own T-cells to recognize and attack cancer cells, have shown promise in other hematologic malignancies and are now being explored for AML. However, because these therapies are manufactured from patient-derived cells, it's critical to confirm that leukemic blasts are not inadvertently included in the final therapeutic product – underscoring the need for sensitive, validated assays like those offered by Invivoscribe and its global accredited regional laboratories, LabPMM.
Article content
LabPMM's CAP/CLIA-Validated AML MRD MFC assay, which was designed to quantify residual leukemic cells in patients undergoing treatment, was customized to meet two critical needs in CERo's drug development program: (1) assessing the purity of the manufactured T-cell product by detecting residual AML blasts prior to infusion, and (2) evaluating therapeutic response to CER-1236 during the trial.
Article content
Kristen Pierce, Ph.D., CERo Chief Development Officer, commented, 'Invivoscribe has played an integral role in the execution of this clinical trial. Its technology and expertise have facilitated our advancement into the clinic by helping to ensure the purity of our investigational product, and now we are reaping the benefits of our collaboration as the trial is underway and we seek to assess therapeutic response.'
Article content
This collaborative effort was instrumental in advancing CER-1236, which recently received FDA Orphan Drug Designation for the treatment of AML 2. The designation highlights the growing urgency of integrated diagnostic support in the advancement of personalized immunotherapies and reflects Invivoscribe's commitment to driving innovation and standardization across the oncology treatment landscape – now helping bring immunotherapies to patients faster.
Article content
For more information about LabPMM's flow cytometry and molecular testing services, please visit https://invivoscribe.com/clinical-lab-services/ or contact us at inquiry@invivoscribe.com and follow us on LinkedIn.
Article content
About Invivoscribe Inc.
Article content
Invivoscribe ® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics ®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM ®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.
Article content
About CERo Therapeutics Holdings, Inc.
Article content
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
26 minutes ago
- Globe and Mail
BrightSpring Health Services, Inc. to Announce Second Quarter 2025 Financial Results on August 1, 2025
LOUISVILLE, Ky., July 08, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ('BrightSpring' or the 'Company') (NASDAQ: BTSG) announced today that it plans to release its second quarter 2025 financial results on Friday, August 1, 2025, prior to the Company's earnings conference call, which will be held at 8:30 a.m. ET on the same day. To participate in the conference call, please register here before the 8:30 a.m. ET start. A live and archived webcast of the call will be available on the Company's investor relations website at under the 'Events & Presentations' section, where related presentation materials will be posted prior to the conference call. The webcast may be accessed directly here. About BrightSpring Health Services BrightSpring Health Services provides complementary home- and community-based pharmacy and provider health solutions for complex populations in need of specialized and/or chronic care. Through the Company's service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive and more integrated care and clinical solutions in all 50 states to over 450,000 customers, clients and patients daily. BrightSpring has consistently demonstrated strong and often industry-leading quality metrics across its services lines while improving the quality of life and health for high-need individuals and reducing overall costs to the healthcare system. Contact Investor Relations: David Deuchler, CFA Gilmartin Group LLC ir@ Media Contact: Leigh White 502.630.7412
National Post
28 minutes ago
- National Post
Barbie® Introduces First-Ever Barbie Doll with Type 1 Diabetes to Expand Representation and Inspire More Children
Article content Barbie partnered with Breakthrough T1D (formerly JDRF) to create the bespoke doll in the brand's global Fashionistas lineup The brand also honored two global role models and type 1 diabetes advocates, Peloton instructor Robin Arzón and model Lila Moss, with their own one-of-a-kind Barbie dolls made in their likeness Article content EL SEGUNDO, Calif. — Mattel, Inc. (NASDAQ: MAT) announced today that Barbie® is debuting the first Barbie doll with type 1 diabetes (T1D). This addition to the line enables more children to see themselves reflected in Barbie and encourages doll play that extends beyond a child's own lived experience, thereby fostering a greater sense of inclusion and empathy – all pillars of the Barbie brand's mission. Article content 'Introducing a Barbie doll with type 1 diabetes marks an important step in our commitment to inclusivity and representation,' said Krista Berger, Senior Vice President of Barbie and Global Head of Dolls. 'Barbie helps shape children's early perceptions of the world, and by reflecting medical conditions like T1D, we ensure more kids can see themselves in the stories they imagine and the dolls they love.' To ensure the doll design truly captures the community, Barbie partnered with Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes research and advocacy organization committed to accelerating life-changing breakthroughs to cure, prevent, and treat type 1 diabetes and its complications. T1D is a chronic autoimmune condition that causes the pancreas to make very little insulin or none at all, leading to dependence on insulin therapy and the risk of short and or long-term complications. Barbie worked closely with Breakthrough T1D to accurately reflect the medical equipment those with this condition may utilize and the doll's look, all the way down to the dress pattern: Article content Continuous Glucose Monitor (CGM): The doll wears a CGM on her arm to help manage her type 1 diabetes. CGMs are small, wearable devices that continuously measure a person's blood-sugar levels. To keep her CGM in place, she uses heart-shaped medical tape – Barbie pink, of course – along with a phone that displays a CGM app to help track her blood sugar levels throughout the day. Insulin Pump: Barbie has an insulin pump, a small, wearable medical device that allows for automated insulin dosing as needed, attached to her waist. Blue Polka Dot Outfit: The doll wears a stylish polka dot top and matching skirt with ruffles. Both the color blue and circle print are nods to the global symbols that represent diabetes awareness. Purse: The doll comes with a pastel blue purse, perfect for Barbie to carry any essentials, such as type 1 diabetes supplies or snacks, when she's on the go. Article content 'We were thrilled when Barbie approached us to collaborate on the development of the Barbie doll with type 1 diabetes,' said Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D. 'I have lived with T1D since I was 13, and my brother since he was 3, so this partnership is deeply personal – it means the world to be part of bringing greater visibility to a condition that affects so many families. It's an honor to work with a brand that shares our commitment to showing children that a life with type 1 diabetes can be full, vibrant, and empowering.' In continued partnership with Breakthrough T1D, Barbie donated dolls to the Breakthrough T1D 2025 Children's Congress. The biennial event, July 7-9, brings 170 children living with type 1 diabetes, ages 4-17, to Washington, DC, to meet face-to-face with members of Congress. The youth delegates travel to the nation's capital from all 50 states and Breakthrough T1D's international affiliates in the United Kingdom, Australia, Israel, the Netherlands, and Canada. Article content Barbie also honored two global role models and type 1 diabetes advocates – Peloton Instructor Robin Arzón in the US and model Lila Moss in the UK – with their own one-of-a-kind Barbie dolls. Arzón unveiled the new Barbie doll with type 1 diabetes and her one-of-a-kind Barbie doll at Peloton Studios NY on July 8th. Attendees and Members of the type 1 diabetes community were delighted to experience this first-of-its-kind unveiling moment. Article content 'After being diagnosed with type 1 diabetes a decade ago, I've found a lot of purpose in advocating for people with the condition and educating others about it because knowledge is power – especially for young minds,' said Arzón. 'It's an absolute honor to receive a Barbie doll as a part of the brand's efforts to grow awareness and representation surrounding type 1 diabetes, so that we can help show kids that all types of challenges give us all the more reason to push forward and achieve our dreams.' Article content Lila Moss says, 'I am proud to use my platform to educate around type 1 diabetes and show that being different is cool. Receiving messages from people who see my patches and feel represented means everything to me. To be able to now see Barbie dolls with T1D, and to receive a Barbie doll that visibly looks like me even wearing her patches, is both surreal and special.' Article content The Barbie Fashionistas line features more than 175 looks across various skin tones, eye colors, hair colors and textures, body types, disabilities, and fashion styles, including a Blind Barbie doll, a Barbie doll with Down Syndrome, and a Barbie doll with Hearing Aids, among others. In 2020, Barbie kicked off a multi-year study with researchers at Cardiff University on the short-term and long-term benefits of doll play. It has been found that doll play serves an incredible purpose during key developmental stages, as it may help set children on a course for success by fostering empathy and developing social skills needed to excel, all while imagining their futures on an equal playing field. Article content The 2025 Barbie Fashionistas dolls commit to a minimum of 50% ISCC-Certified bio-circular plastic (Mass Balance Approach), with all boxes made from FSC-certified materials. By incorporating ISCC-certified plastic into these dolls, Barbie aims to reduce reliance on fossil-based materials in support of a more circular economy. Article content The 2025 Barbie Fashionistas dolls, including the Barbie doll with Type 1 diabetes, are now available on Mattel Shop and at retailers nationwide. Article content About Mattel Article content Mattel is a leading global toy and family entertainment company and owner of one of the most iconic brand portfolios in the world. We engage consumers and fans through our franchise brands, including Barbie®, Hot Wheels®, Fisher-Price®, American Girl®, Thomas & Friends™, UNO®, Masters of the Universe®, Matchbox®, Monster High®, MEGA® and Polly Pocket®, as well as other popular properties that we own or license in partnership with global entertainment companies. Our offerings include toys, content, consumer products, digital and live experiences. Our products are sold in collaboration with the world's leading retail and ecommerce companies. Since its founding in 1945, Mattel is proud to be a trusted partner in empowering generations to explore the wonder of childhood and reach their full potential. Visit us at Article content As the leading global type 1 diabetes (T1D) research and advocacy organization, Breakthrough T1D (formerly JDRF) helps make everyday life with type 1 diabetes better while driving toward cures. We do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition. Article content About Type 1 Diabetes (T1D) Article content T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short and long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death. Globally, it impacts nearly 9 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D. Article content Article content Article content Article content Article content Contacts Article content News Media Article content Article content Devin Duff Article content
CTV News
2 hours ago
- CTV News
Wildfires taking a toll on mental health: research
Soodeh Saberian, associate professor of economics, reveals how wildfires affect not only lungs — but minds, stress levels, and hospital visits too.
